

DAFTAR PUSTAKA

- Abraham, G.R., Nyimanu, D., Kuc, R.E., Maguire, J.J., Davenport, A.P., *et al.*, 2022. Trans-myocardial Extraction of Endothelin-1 Correlates with Increased Microcirculatory Resistance following Percutaneous Coronary Intervention. *J. Interv. Cardiol.* 2022. doi:10.1155/2022/9154048
- Al-Lamee, R., Thompson, D., Dehbi, H.M., Sen, S., Tang, K., *et al.*, 2018. Percutaneous Coronary Intervention in Stable Angina (ORBITA): A Double-Blind, Randomized Controlled Trial. *J. Vasc. Surg.* 67: 673. doi:10.1016/j.jvs.2017.11.046
- Al-Lamee, R.K., Nowbar, A.N., & Francis, D.P., 2019. Percutaneous coronary intervention for stable coronary artery disease. *Heart* 105: 11–19. doi:10.1136/heartjnl-2017-312755
- Ameli, S., Kaul, S., Castro, L., Arora, C., Mirea, A., *et al.*, 1993. Effect of percutaneous transluminal coronary angioplasty on circulating endothelin levels. *Am. J. Cardiol.* 72: 1352–1356. doi:10.1016/0002-9149(93)90178-F
- American Heart Association, 2021. 2021 Heart Disease & Stroke Statistical Update Fact Sheet Global Burden of Disease High Blood Cholesterol and Other Lipids. *Am. Hear. Assoc.* 2019–2021.
- Antzelevitch, C., & Burashnikov, A., 2011. Overview of Basic Mechanisms of Cardiac Arrhythmia. *Card. Electrophysiol. Clin.* 3: 23–45. doi:10.1016/j.ccep.2010.10.012
- Arnott, C., Li, Q., Kang, A., Neuen, B.L., Bompont, S., *et al.*, 2020. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *J. Am. Heart Assoc.* 9. doi:10.1161/JAHA.119.014908
- Battistelli, S., Billi, M., Manasse, G., Vittoria, A., Roviello, F., *et al.*, 1999. Behavior of circulating endothelin-1 in a group of patients with acute myocardial infarction. *Angiology* 50: 629–638. doi:10.1177/000331979905000803
- Behnouch, A.H., Khalaji, A., Naderi, N., Ashraf, H., & von Haehling, S., 2023. ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. *ESC Hear. Fail.* 10: 1531–1544. doi:10.1002/ehf2.14255
- Böhm, F., & Pernow, J., 2007. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. *Cardiovasc. Res.* 76: 8–18. doi:10.1016/j.cardiores.2007.06.004
- Bosco, E., Hsueh, L., McConeghy, K.W., Gravenstein, S., & Saade, E., 2021. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. *BMC Med. Res. Methodol.* 21: 1–18. doi:10.1186/s12874-021-01440-5
- Braun, M.M., & Stevens, W.A., 2018. Stable Coronary Artery Disease: Treatment. *Am. Fam. Physician* 97: 376–384.
- Brouwers, F.P., Van Gilst, W.H., Damman, K., Van Den Berg, M.P., Gansevoort, R.T., *et al.*, 2014. Clinical risk stratification optimizes value of biomarkers to

- predict new-onset heart failure in a community-based cohort. *Circ. Hear. Fail.* 7: 723–731. doi:10.1161/CIRCHEARTFAILURE.114.001185
- Byrne, R.A., Rossello, X., Coughlan, J.J., Barbato, E., Berry, C., *et al.*, 2023. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur. Heart J.* 44: 3720–3826. doi:10.1093/eurheartj/ehad191
- Cardillo, C., Kilcoyne, C.M., Cannon, R.O., & Panza, J.A., 2000. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. *Hypertension* 35: 1237–1241. doi:10.1161/01.HYP.35.6.1237
- Conte, S.M., & Vale, P.R., 2018. Peripheral Arterial Disease. *Hear. Lung Circ.* 27: 427–432. doi:10.1016/j.hlc.2017.10.014
- Davidson, M.H., 2012. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: Therapeutic approaches to improve outcomes: Perspectives of a preventive cardiologist. *Am. J. Cardiol.* 110: 43B–49B. doi:10.1016/j.amjcard.2012.08.033
- Eitel, I., Nowak, M., Stehl, C., Adams, V., Fuernau, G., *et al.*, 2010. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. *Am. Heart J.* 159: 882–890. doi:10.1016/j.ahj.2010.02.019
- Fadia Mayyasa, , Mohammad Al-Jarrahb, C., , Khalid Ibrahim, d, Doaa Mfadya, and D.R. Van, & Wagonere, 2015. The significance of circulating endothelin-1 as a predictor of coronary artery disease status and clinical outcomes following coronary artery catheterization. *Cardiovasc. Pathol. / J.* 24: 19–25. doi:10.1016/j.carpath.2014.08.004.
- Fitchett, D.H., Theroux, P., Brophy, J.M., & Goodman, S.G., 2011. Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction. *CJCA* 27: S402–S412. doi:10.1016/j.cjca.2011.08.107
- Ford, T.J., Corcoran, D., & Berry, C., 2018. Stable coronary syndromes: Pathophysiology, diagnostic advances and therapeutic need. *Heart* 104: 284–292. doi:10.1136/heartjnl-2017-311446
- Galley, H.F., & Webster, N.R., 2004. Physiology of the endothelium. *Br. J. Anaesth.* 93: 105–113. doi:10.1093/bja/ae163
- Gary, P.H., J.B.M., S.C.T. *et al.*, 1990. The New England Journal of Medicine Downloaded from nejm.org on April 1, 2015. For personal use only. No other uses without permission. Copyright © 1990 Massachusetts Medical Society. All rights reserved. *New English J. Med.* 323: 1120–1123.
- Greendale, G.A., Lee, N.P., & Arriola, E.R., 1999. The menopause. *Lancet* 353: 571–580. doi:10.1016/S0140-6736(98)05352-5
- Hartopo, A.B., Fachiroh, J., Puspitawati, I., & Dewi, F.S.T., 2021. Serum endothelin-1 level positively correlates with waist and hip circumferences in stable coronary artery disease patients. *Rev. Cardiovasc. Med.* 22: 919–924.

doi:10.31083/J.RCM2203099

- Hartopo, A.B., Sukmasari, I., Puspitawati, I., & Setianto, B.Y., 2020. Serum Endothelin-1 Correlates with Myocardial Injury and Independently Predicts Adverse Cardiac Events in Non-ST-Elevation Acute Myocardial Infarction. *Int. J. Vasc. Med.* 2020. doi:10.1155/2020/9260812
- Hasdai, D., Holmes, D.R., Garratt, K.N., Edwards, W.D., & Lerman, A., 1997. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. *Circulation* 95: 357–362. doi:10.1161/01.CIR.95.2.357
- Jankowich, M., & Choudhary, G., 2020. Endothelin-1 levels and cardiovascular events. *Trends Cardiovasc. Med.* 30: 1–8. doi:10.1016/j.tcm.2019.01.007
- Jankowska, E.A., Filippatos, G.S., von Haehling, S., Papassotiriou, J., Morgenthaler, N.G., *et al.*, 2011. identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. *PLoS One* 6. doi:10.1371/journal.pone.0014506
- Jebari-Benslaiman, S., Galicia-García, U., Larrea-Sebal, A., Olaetxea, J.R., Alloza, I., *et al.*, 2022. Pathophysiology of Atherosclerosis. *Int. J. Mol. Sci.* 23: 1–38. doi:10.3390/ijms23063346
- Katrtsis, D.G., & Meier, B., 2008. Percutaneous Coronary Intervention for Stable Coronary Artery Disease. *J. Am. Coll. Cardiol.* 52: 889–893. doi:10.1016/j.jacc.2008.05.048
- Khan, M.A., Hashim, M.J., Mustafa, H., Baniyas, M.Y., Al Suwaidi, S.K.B.M., *et al.*, 2020. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. *Cureus* 12. doi:10.7759/cureus.9349
- Klein, L., & Gheorghiade, M., 2004. Coronary artery disease and prevention of heart failure. *Med. Clin. North Am.* 88: 1209–1235. doi:10.1016/j.mcna.2004.03.002
- Kobayashi, S., Wakeyama, T., Ono, S., Ikeda, Y., Omura, M., *et al.*, 2020. A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. *J. Cardiol.* 75: 454–461. doi:10.1016/j.jjcc.2019.08.020
- Kostov, K., & Blazhev, A., 2021. Circulating levels of endothelin-1 and big endothelin-1 in patients with essential hypertension. *Pathophysiology* 28: 489–495. doi:10.3390/pathophysiology28040031
- Kowalczyk, A., Kleniewska, P., Kolodziejczyk, M., Skibska, B., & Goraca, A., 2015. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. *Arch. Immunol. Ther. Exp. (Warsz.)*. 63: 41–52. doi:10.1007/s00005-014-0310-1
- Kru, D., Giannitsis, E., & Sheikhzadeh, A., 1998. Cardiac Release and Kinetics of Endothelin After Uncomplicated Percutaneous Transluminal Coronary Angioplasty. *Am. J. Cardiol.* 9149: 1421–1426.
- Libby, P., & Theroux, P., 2005. Pathophysiology of coronary artery disease.

- Circulation* 111: 3481–3488. doi:10.1161/CIRCULATIONAHA.105.537878
- Lin, R., Juntila, J., Piihola, J., Lepojärvi, E.S., Magga, J., *et al.*, 2023. Endothelin-1 is associated with mortality that can be attenuated with high intensity statin therapy in patients with stable coronary artery disease. *Commun. Med.* 3: 1–9. doi:10.1038/s43856-023-00322-9
- Liou, K., 2018. Evaluation of the Interaction Between Endothelin Antagonism, the Coronary Microcirculation, Coronary Inflammation and Cardiac Function in Patients Undergoing Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome.
- Loennechen, J.P., Støylen, A., Beisvag, V., Wisløff, U., & Ellingsen, Ø., 2001. Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart. *Am. J. Physiol. - Hear. Circ. Physiol.* 280: 2902–2910. doi:10.1152/ajpheart.2001.280.6.h2902
- Lu, T.M., Tai, C.T., Hsieh, M.H., Tsai, C.F., Lin, Y.K., *et al.*, 2001. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future? *J. Am. Coll. Cardiol.* 37: 1493–1505. doi:10.1016/S0735-1097(01)01210-4
- Ma, Y., Tian, T., Wang, T., Wang, J., Guan, H., *et al.*, 2022. Predictive Value of Plasma Big Endothelin-1 in Adverse Events of Patients With Coronary Artery Restenosis and Diabetes Mellitus: Beyond Traditional and Angiographic Risk Factors. *Front. Cardiovasc. Med.* 9: 1–12. doi:10.3389/fcvm.2022.854107
- Maguire, J.J., & Davenport, A.P., 2015. Endothelin Receptors and Their Antagonists. *Semin. Nephrol.* 35: 125–136. doi:10.1016/j.semnephrol.2015.02.002
- Malatino, L.S., Grassi, R., Stancanelli, B., Polizzi, G., Leonardi, C., *et al.*, 1993. Release of immunoreactive endothelin from the heart during percutaneous transluminal coronary angioplasty. *Am. Heart J.* 126: 700–702. doi:10.1016/0002-8703(93)90421-5
- Marasciulo, F., Montagnani, M., & Potenza, M., 2006. Endothelin-1: The Yin and Yang on Vascular Function. *Curr. Med. Chem.* 13: 1655–1665. doi:10.2174/092986706777441968
- Masson, S., Latini, R., Carbonieri, E., Moretti, L., Rossi, M.G., *et al.*, 2010. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: Data from the GISSI-heart failure (GISSI-HF) trial. *Eur. J. Heart Fail.* 12: 338–347. doi:10.1093/eurjhf/hfp206
- Miao, B., Hernandez, A. V., Alberts, M.J., Mangiafico, N., Roman, Y.M., *et al.*, 2020. Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors. *J. Am. Heart Assoc.* 9. doi:10.1161/JAHA.119.014402
- Miyauchi, T., & Masaki, T., 1999. Pathophysiology of endothelin in the cardiovascular system. *Annu. Rev. Physiol.* 61: 391–415. doi:10.1146/annurev.physiol.61.1.391
- Neumann, F.J., Sechtem, U., Banning, A.P., Bonaros, N., Bueno, H., *et al.*, 2020. 2019 ESC Guidelines for the diagnosis and management of chronic coronary

- syndromes. *Eur. Heart J.* 41: 407–477. doi:10.1093/eurheartj/ehz425
- PERKI, 2022. Panduan Prevensi Penyakit Kardiovaskular Arteriosklerosis, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia 2022.
- Petronio, A.S., Amoroso, G., Limbruno, U., Baglini, R., Paterni, G., *et al.*, 1999. Endothelin-1 release from atherosclerotic plaque after percutaneous transluminal coronary angioplasty in stable angina pectoris and single-vessel coronary artery disease. *Am. J. Cardiol.* 84: 1085–1088. doi:10.1016/S0002-9149(99)00505-6
- Poudel, I., Tejpal, C., Rashid, H., & Jahan, N., 2019a. Major Adverse Cardiovascular Events: An Inevitable Outcome of ST-elevation myocardial infarction? A Literature Review. *Cureus* 11. doi:10.7759/cureus.5280
- Poudel, I., Tejpal, C., Rashid, H., & Jahan, N., 2019b. Major Adverse Cardiovascular Events: An Inevitable Outcome of ST-elevation myocardial infarction? A Literature Review. *Cureus* 11: 1–9. doi:10.7759/cureus.5280
- Sabatine, M.S., Morrow, D.A., Lemos, J.A. De, Omland, T., Sloan, S., *et al.*, 2013. Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients with Stable Coronary Disease. *NIH Public Access* 125: 233–240. doi:10.1161/CIRCULATIONAHA.111.063842.Evaluation
- Schnabel, R.B., Schulz, A., Messow, C.M., Lubos, E., Wild, P.S., *et al.*, 2010. Multiple marker approach to risk stratification in patients with stable coronary artery disease. *Eur. Heart J.* 31: 3024–3031. doi:10.1093/eurheartj/ehq322
- Seligman, B.G.S., Biolo, A., Polanczyk, C.A., Gross, J.L., & Clausell, N., 2000. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. *Diabetes Care* 23: 1395–1400. doi:10.2337/diacare.23.9.1395
- Silberberg, J.S., Wlodarczyk, J., Fryer, J., Robertson, R., & Hensley, M.J., 1998. Risk associated with various definitions of family history of coronary heart disease the newcastle family history study II. *Am. J. Epidemiol.* 147: 1133–1139. doi:10.1093/oxfordjournals.aje.a009411
- Torpy, J.M., Burke, A.E., & Glass, R.M., 2009. Coronary heart disease risk factors. *Jama* 302: 2388. doi:10.1001/jama.302.21.2388
- Tsai, I.T., Wang, C.P., Lu, Y.C., Hung, W.C., Wu, C.C., *et al.*, 2017. The burden of major adverse cardiac events in patients with coronary artery disease. *BMC Cardiovasc. Disord.* 17: 1–13. doi:10.1186/s12872-016-0436-7
- Tsutamoto, T., Wada, A., Hayashi, M., Tsutsui, T., Maeda, K., *et al.*, 2003. Relationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction. *Eur. Heart J.* 24: 346–355. doi:10.1016/S0195-668X(02)00420-7
- Verma, S., Bain, S.C., Buse, J.B., Idorn, T., Rasmussen, S., *et al.*, 2019. Occurrence of First and Recurrent Major Adverse Cardiovascular Events with Liraglutide Treatment among Patients with Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.

- JAMA Cardiol.* 4: 1214–1220. doi:10.1001/jamacardio.2019.3080
- Vojáček, J., Kolář, J., Lisý, O., Hraboš, V., Šimek, S., *et al.*, 1999. Time course of endothelin-1 plasma level in patients with acute coronary syndromes. *Cardiology* 91: 114–118. doi:10.1159/000006890
- Wang, F., Li, T., Cong, X., Hou, Z., Lu, B., *et al.*, 2019. Association between circulating big endothelin-1 and noncalcified or mixed coronary atherosclerotic plaques. *Coron. Artery Dis.* 30: 461–466. doi:10.1097/MCA.0000000000000752
- Wang, H., & Wang, C., 2023. Prognostic Value of Endothelin-1 or Related Peptides in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis. *Angiology* 0: 1–9. doi:10.1177/00033197231223616
- Xaplanteris, P., Fournier, S., Pijls, N.H.J., Fearon, W.F., Barbato, E., *et al.*, 2018. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. *N. Engl. J. Med.* 379: 250–259. doi:10.1056/nejmoa1803538
- Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., *et al.*, 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*. doi:10.1038/332411a0
- Yip, H.K., Wu, C.J., Chang, H.W., Yang, C.H., Yu, T.H., *et al.*, 2005. Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. *Chest* 127: 1491–1497. doi:10.1378/chest.127.5.1491
- Yu, A.P., Tam, B.T., Yau, W.Y., Chan, K.S., Yu, S.S., *et al.*, 2015. Association of endothelin-1 and matrix metalloproteinase-9 with metabolic syndrome in middle-aged and older adults. *Diabetol. Metab. Syndr.* 7: 1–13. doi:10.1186/s13098-015-0108-2
- Zhou, B.Y., Guo, Y.L., Wu, N.Q., Zhu, C.G., Gao, Y., *et al.*, 2017. Plasma big endothelin-1 levels at admission and future cardiovascular outcomes: A cohort study in patients with stable coronary artery disease. *Int. J. Cardiol.* 230: 76–79. doi:10.1016/j.ijcard.2016.12.082